How do I even get reta right now? Is it available anywhere? — need advice

TrialTracker_MD said:

The distinction that resolves most of these threads is between what is true on average and what is true for one person.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

I would rather be corrected than agreed with, if it comes to it.

Adding the numbers, since they settle part of this. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

PharmD_Rodriguez said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

Adding the part of the answer the thread has not reached. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

That is the short version; the long version is somebody else's post.

A narrower follow-up, since the general answer is now clear:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

OP back with an update, since a thread like this is useless without one.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.